Trial Profile
Stimulation of tyrosine kinase and ERK [extracellular signal-regulated kinase] signaling pathways in Huntington's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lithium (Primary) ; Valproate semisodium (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 26 Mar 2008 New trial record.